Health ❯ Healthcare ❯ Clinical Trials

Phase 2 Trials

eNRGy Trial Vaccine Efficacy Dostarlimab Weight Loss Studies Clinical Study Results Silevertinib Trials WILLOW Trial AMT-130 NOBILITY Trial Weight Loss Drugs

3 ARTICLES

17h ago

Hanmi Licenses GLP‑2 Drug Sonefpeglutide to Eli Lilly

The deal gives Lilly global development and sales rights outside Korea while Hanmi takes $75 million up front and retains the right to complete its Phase 2 short bowel syndrome trial.

Stories older than 24h

6 ARTICLES

last wk.

FDA Accepts ImmunityBio Filing to Expand ANKTIVA Use in Bladder Cancer

4 ARTICLES

2w ago

Lifeward Completes Oratech Deal and Maps Back‑Half 2026 Recovery After Q1 Setbacks

3 ARTICLES

2w ago

FDA Clears All-Oral Decitabine/Cedazuridine Plus Venetoclax for Older AML Patients

11 ARTICLES

last mo.

Personalized mRNA Vaccine Shows Durable Survival Signal in Early Pancreatic Cancer

3 ARTICLES

last mo.

Cadonilimab Plus Chemo Delivers Strong Phase 2 Signal in Frontline Endometrial Cancer

4 ARTICLES

3mo ago

EMA Panel Backs Conditional EU Approval for Ojemda in Pediatric Low-Grade Glioma

9 ARTICLES

4mo ago

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

9 ARTICLES

4mo ago

Moderna–Merck Personalized Melanoma Vaccine Sustains 5-Year Benefit, Cutting Recurrence Risk by 49%

4 ARTICLES

4mo ago

Amgen Reports Year-Long Weight-Loss Maintenance With Monthly or Quarterly MariTide Dosing

4 ARTICLES

5mo ago

Phase II Trial Finds 24 Gy Preoperative Radiation With Pembrolizumab Boosts T‑Cell Infiltration in HR+/HER2− Breast Cancer

5 ARTICLES

5mo ago

Structure Therapeutics' Oral GLP-1 Posts Up to 15% Placebo-Adjusted Weight Loss as Company Prepares Phase 3

5 ARTICLES

5mo ago

KOMET-007 Shows 600 mg Ziftomenib Plus Venetoclax/Azacitidine Achieves Deep Remissions in NPM1‑Mutated AML

3 ARTICLES

5mo ago

FDA Approves Breyanzi for Marginal Zone Lymphoma After Two or More Therapies

3 ARTICLES

6mo ago

Silevertinib Delivers 60% Response and Strong CNS Activity in First-Line NSCLC With Non-Classical EGFR Mutations

3 ARTICLES

6mo ago

10-Minute UCL Scan Pinpoints Source of Aldosterone Excess in Hypertension

4 ARTICLES

6mo ago

FDA Approves Epkinly Monotherapy and Triplet Regimen for Relapsed Follicular Lymphoma

5 ARTICLES

7mo ago

FDA Approves Gazyva for Adults With Active Lupus Nephritis

6 ARTICLES

8mo ago

Perioperative Immunotherapy and Liquid Biopsy Show Promise in Resectable Mesothelioma Phase 2 Trial

4 ARTICLES

8mo ago

B7-H3 ADC Ifinatamab Deruxtecan Shows 48% Response in Relapsed ES-SCLC in Phase 2

Phase 2 Trials

Hanmi Licenses GLP‑2 Drug Sonefpeglutide to Eli Lilly

FDA Accepts ImmunityBio Filing to Expand ANKTIVA Use in Bladder Cancer

Lifeward Completes Oratech Deal and Maps Back‑Half 2026 Recovery After Q1 Setbacks

FDA Clears All-Oral Decitabine/Cedazuridine Plus Venetoclax for Older AML Patients

Personalized mRNA Vaccine Shows Durable Survival Signal in Early Pancreatic Cancer

Cadonilimab Plus Chemo Delivers Strong Phase 2 Signal in Frontline Endometrial Cancer

EMA Panel Backs Conditional EU Approval for Ojemda in Pediatric Low-Grade Glioma

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

Moderna–Merck Personalized Melanoma Vaccine Sustains 5-Year Benefit, Cutting Recurrence Risk by 49%

Amgen Reports Year-Long Weight-Loss Maintenance With Monthly or Quarterly MariTide Dosing

Never miss stories about

Phase 2 Trials

Phase II Trial Finds 24 Gy Preoperative Radiation With Pembrolizumab Boosts T‑Cell Infiltration in HR+/HER2− Breast Cancer

Structure Therapeutics' Oral GLP-1 Posts Up to 15% Placebo-Adjusted Weight Loss as Company Prepares Phase 3

KOMET-007 Shows 600 mg Ziftomenib Plus Venetoclax/Azacitidine Achieves Deep Remissions in NPM1‑Mutated AML

FDA Approves Breyanzi for Marginal Zone Lymphoma After Two or More Therapies

Silevertinib Delivers 60% Response and Strong CNS Activity in First-Line NSCLC With Non-Classical EGFR Mutations

10-Minute UCL Scan Pinpoints Source of Aldosterone Excess in Hypertension

FDA Approves Epkinly Monotherapy and Triplet Regimen for Relapsed Follicular Lymphoma

FDA Approves Gazyva for Adults With Active Lupus Nephritis

Perioperative Immunotherapy and Liquid Biopsy Show Promise in Resectable Mesothelioma Phase 2 Trial

B7-H3 ADC Ifinatamab Deruxtecan Shows 48% Response in Relapsed ES-SCLC in Phase 2

Never miss stories about

Phase 2 Trials